Immune thrombocytopenia(ITP) is an autoimmune disorder characterized by continuously decrease of platelet and the skin mucous membrane bleeding. The autoantibodies against platelet in the blood of ITP patients combine platelets that induces destruction by macrophages in the spleen and insufficient megakaryocyte platelet production. In April 2018, fostamatinib has been approved by the U.S. FDA for the treatment of ITP in adult patients. Fostamatinib is a tyrosine kinase inhibitor with a new mechanism of action. The action mechanism, pharmacodynamics, pharmacoki...
